Lenalidomide induces degradation of IKZF1 and IKZF3

Oncoimmunology. 2014 Jul 3;3(7):e941742. doi: 10.4161/21624011.2014.941742. eCollection 2014.


Lenalidomide and its analogs, thalidomide and pomalidomide, specifically inhibit growth of mature B-cell lymphomas, including multiple myeloma, and induce interleukin-2 (IL-2) release from T cells. We recently found that this results from activation of the CRBN-CRL4 E3 ubiquitin ligase to degrade the lymphoid transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos).

Keywords: lenalidomide; pomalidomide; thalidomide; ubiquitin.